Journal
ONCOTARGET
Volume 7, Issue 50, Pages 82741-82756Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.12633
Keywords
ovarian cancer; targeted therapy; systemic chemotherapy; systematic review; meta-analysis
Categories
Funding
- PhD program of Magna Graecia University: molecular oncology and translational and innovative medical and surgical techniques
Ask authors/readers for more resources
Objectives: The current gold-standard for the first-line treatment in IIIb/IV stages of epithelial ovarian cancer (EOC) is the combination of carboplatin and paclitaxel plus bevacizumab in some countries. In the era of personalized medicine, there is still uncertainty on the impact of several molecularly targeted agents, which have been investigated for the management of this disease. To shed light on the actual role of targeted therapy in EOC, a systematic review and meta-analysis was performed. Methods: Clinical trials were selected by searching Pubmed database and abstracts from major cancer meetings within the time-frame of January 2004-June 2015. The endpoints were survival outcome and response rate (RR). Hazard ratios (HRs) of survival outcomes, with confidence intervals and odds-ratios (ORs) of RR, were extracted from retrieved studies and used for current analysis. Meta-analysis was carried out by random effect model. Results: 30 randomized trials for a total of 10,530 patients were selected and included in the final analysis. A benefit in terms of OS (pooled HR 0.915; 95% CI 0.840-0.997; p=0.043), particularly for anti-angiogenetic agents (HR 0.872; 95% CI 0.761-1.000; p=0.049), has been demonstrated for targeted therapy. Moreover, a significant advantage in platinum-resistant subgroup in term of PFS (HR 0.755; 95% CI 0.624-0.912; p=0.004) was found. Conclusions: This systematic review and meta-analysis provide the first evidence that targeted therapy is potentially able to translate into improved survival of EOC patients, with a major role played by anti-angiogenetic drugs. The role of target therapy is underlined in the platinum-resistant setting that represents the pain in the neck in EOC management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available